118 related articles for article (PubMed ID: 11398810)
1. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans.
Zuffi E; Manaresi E; Gallinella G; Gentilomi GA; Venturoli S; Zerbini M; Musiani M
Viral Immunol; 2001; 14(2):151-8. PubMed ID: 11398810
[TBL] [Abstract][Full Text] [Related]
2. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1.
Musiani M; Manaresi E; Gallinella G; Venturoli S; Zuffi E; Zerbini M
J Med Virol; 2000 Mar; 60(3):347-52. PubMed ID: 10630969
[TBL] [Abstract][Full Text] [Related]
3. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins.
Manaresi E; Zuffi E; Gallinella G; Gentilomi G; Zerbini M; Musiani M
J Med Virol; 2001 May; 64(1):67-73. PubMed ID: 11285571
[TBL] [Abstract][Full Text] [Related]
4. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
5. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
Corcoran A; Mahon BP; Doyle S
J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
[TBL] [Abstract][Full Text] [Related]
6. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG.
Kerr S; O'Keeffe G; Kilty C; Doyle S
J Med Virol; 1999 Feb; 57(2):179-85. PubMed ID: 9892405
[TBL] [Abstract][Full Text] [Related]
7. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay.
Manaresi E; Gallinella G; Zerbini M; Venturoli S; Gentilomi G; Musiani M
J Med Virol; 1999 Feb; 57(2):174-8. PubMed ID: 9892404
[TBL] [Abstract][Full Text] [Related]
8. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
Franssila R; Hedman K
Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
[TBL] [Abstract][Full Text] [Related]
9. Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19.
Söderlund M; Brown CS; Spaan WJ; Hedman L; Hedman K
J Infect Dis; 1995 Dec; 172(6):1431-6. PubMed ID: 7594699
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.
Saikawa T; Anderson S; Momoeda M; Kajigaya S; Young NS
J Virol; 1993 Jun; 67(6):3004-9. PubMed ID: 7684458
[TBL] [Abstract][Full Text] [Related]
11. Candidate recombinant vaccine for human B19 parvovirus.
Bansal GP; Hatfield JA; Dunn FE; Kramer AA; Brady F; Riggin CH; Collett MS; Yoshimoto K; Kajigaya S; Young NS
J Infect Dis; 1993 May; 167(5):1034-44. PubMed ID: 8486937
[TBL] [Abstract][Full Text] [Related]
12. Detection of parvovirus B19 IgG: choice of antigens and serological tests.
Manaresi E; Gallinella G; Venturoli S; Zerbini M; Musiani M
J Clin Virol; 2004 Jan; 29(1):51-3. PubMed ID: 14675870
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donors.
Manaresi E; Gallinella G; Morselli Labate AM; Zucchelli P; Zaccarelli D; Ambretti S; Delbarba S; Zerbini M; Musiani M
Epidemiol Infect; 2004 Oct; 132(5):857-62. PubMed ID: 15473148
[TBL] [Abstract][Full Text] [Related]
14. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins.
Gigler A; Dorsch S; Hemauer A; Williams C; Kim S; Young NS; Zolla-Pazner S; Wolf H; Gorny MK; Modrow S
J Virol; 1999 Mar; 73(3):1974-9. PubMed ID: 9971777
[TBL] [Abstract][Full Text] [Related]
15. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.
Rosenfeld SJ; Yoshimoto K; Kajigaya S; Anderson S; Young NS; Field A; Warrener P; Bansal G; Collett MS
J Clin Invest; 1992 Jun; 89(6):2023-9. PubMed ID: 1376332
[TBL] [Abstract][Full Text] [Related]
16. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection.
Pfrepper KI; Enders M; Motz M
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):362-5. PubMed ID: 16316402
[TBL] [Abstract][Full Text] [Related]
17. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
Bostic JR; Brown KE; Young NS; Koenig S
J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
[TBL] [Abstract][Full Text] [Related]
19. Generation of a parvovirus B19 vaccine candidate.
Chandramouli S; Medina-Selby A; Coit D; Schaefer M; Spencer T; Brito LA; Zhang P; Otten G; Mandl CW; Mason PW; Dormitzer PR; Settembre EC
Vaccine; 2013 Aug; 31(37):3872-8. PubMed ID: 23827313
[TBL] [Abstract][Full Text] [Related]
20. Impaired gamma interferon responses against parvovirus B19 by recently infected children.
Corcoran A; Doyle S; Waldron D; Nicholson A; Mahon BP
J Virol; 2000 Nov; 74(21):9903-10. PubMed ID: 11024117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
